FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973138923> ?p ?o ?g. }

• W2973138923 endingPage "E279" @default.
• W2973138923 startingPage "E278" @default.
• W2973138923 abstract "There is a little clinical data to the use of statins and new androgen receptor inhibitors (ARIs) in patients with mCRPC. Statins can enhance the effect of new ARIs in patients with mCRPC through a competitive interactions, decreasing the recruitment as an androgenic precursor. The aim of the study is to determine whether the use of statins with new ARIs has a clinical impact on survival in patients with mCRPC. Patients diagnosed of mCRPC and treated with new ARIs without previous chemotherapy were included. The patients were stratified by statins or non-statins. We described categorical and continuous variables in each group. Comparisons of survival rates were performed using log rank statistics. Multivariate analysis was performed with Cox regression modelling. Value of p < .05 was set as significant. The variables studied were: hemoglobin, lymphocytes, alkaline phosphatase, pain, use of opioids, type of ARIs, radiotherapy, androgen deprivation (AD), prostate-specific-antigen (PSA) at diagnosis, nadir PSA and statins and PSA response at 4, 8, 12, and16 weeks. Between April 2009 and August 2018, 64 patients (42 Abidaterone and 22 Enzalutamide) were included. The median survival of the entire cohort of patients was 40.8 months (95% CI 33.64 – 48.08). Overall survival (OS) was 43.2 months for the statin group (95% CI 36.98 – 49.41, p = 0.035) and 29.7 months for the non-statin group (95% CI 23.45 – 36.01). Progression-free survival (PFS) was 18 months for the statin group (95% CI 8.64 – 27.35, p = 0.004) and 7 months for the non-statin group (95% CI 4.60 – 9.39). No relationship was observed between statins and the lowering of PSA at 4, 8, 12 and 16 weeks compared to the non-statin group (P = ns). On multivariate analysis, factors associated to survival were LDH (HR 1,007, CI 95%, 1,002 – 1,013, p = 0.01), Neutrophils (HR 1,001, CI 95% 1,000 – 1,001, p = 0.049), and statins (HR 2,790, CI 95% 1,011 – 7,698, p = 0.045). In this retrospective cohort, the use of statins increases overall and progression-free survival compared to the use of ARIs without statins in mCRPC. Factors associated to survival were LDH, neutrophils, and statins. Statins do not modify the PSA response in the first 4 months of treatment.Abstract 2642; Table 1Patient characteristicsSTATINS (n = 32 ptes)Not STATINS (n = 32 ptes)pMedian age at diagnosis (range)69,8 years (46 – 85)67,9 years (43 – 86)0.415KPS <80 >8010 (31%) 22 (69%)10 (31%) 22 (69%)0.6Gleason score <7 8 - 1012 (37,5%) 20 (62,5%)15 (46,9%) 17 (53,1%)0.133Initial clinical stage Localized Metastatic13 (40,6%) 19 (59,4%)15 (46,9%) 17 (53,1%)0.614Time to CRPC months (range)62,5m (6 – 144m)59,09m (3 – 192m)0.755KPS at CRPC >80 <8015 (46,9%) 17 (53,1%)11 (34,4%) 21 (65,6%)0.309Alkaline phosphate (U/L)280 (58 – 452)365 (98 – 784)0.127LDH (U/L)338 (54 – 1074)552 (102 – 1990)0.019PSA (ng/ml)72,8 (1,14 – 368)96,7 (0,97 – 1006)0.503Type of AD Abiraterone Enzalutamide21 (65,6%) 11 (34,4%)21 (65,6%) 11 (34,4%)0.604 Open table in a new tab" @default.
• W2973138923 created "2019-09-19" @default.
• W2973138923 creator A5013885115 @default.
• W2973138923 creator A5030148889 @default.
• W2973138923 creator A5036173025 @default.
• W2973138923 creator A5038351166 @default.
• W2973138923 creator A5041379159 @default.
• W2973138923 creator A5053359424 @default.
• W2973138923 creator A5074914001 @default.
• W2973138923 creator A5079831250 @default.
• W2973138923 creator A5086927677 @default.
• W2973138923 date "2019-09-01" @default.
• W2973138923 modified "2023-10-16" @default.
• W2973138923 title "Influence of Statins on Survival Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Inhibitors" @default.
• W2973138923 doi "https://doi.org/10.1016/j.ijrobp.2019.06.1908" @default.
• W2973138923 hasPublicationYear "2019" @default.
• W2973138923 type Work @default.
• W2973138923 sameAs 2973138923 @default.
• W2973138923 citedByCount "2" @default.
• W2973138923 countsByYear W29731389232022 @default.
• W2973138923 crossrefType "journal-article" @default.
• W2973138923 hasAuthorship W2973138923A5013885115 @default.
• W2973138923 hasAuthorship W2973138923A5030148889 @default.
• W2973138923 hasAuthorship W2973138923A5036173025 @default.
• W2973138923 hasAuthorship W2973138923A5038351166 @default.
• W2973138923 hasAuthorship W2973138923A5041379159 @default.
• W2973138923 hasAuthorship W2973138923A5053359424 @default.
• W2973138923 hasAuthorship W2973138923A5074914001 @default.
• W2973138923 hasAuthorship W2973138923A5079831250 @default.
• W2973138923 hasAuthorship W2973138923A5086927677 @default.
• W2973138923 hasBestOaLocation W29731389231 @default.
• W2973138923 hasConcept C121608353 @default.
• W2973138923 hasConcept C126322002 @default.
• W2973138923 hasConcept C126894567 @default.
• W2973138923 hasConcept C143998085 @default.
• W2973138923 hasConcept C2776551883 @default.
• W2973138923 hasConcept C2776839432 @default.
• W2973138923 hasConcept C2777899217 @default.
• W2973138923 hasConcept C2777911890 @default.
• W2973138923 hasConcept C2780192828 @default.
• W2973138923 hasConcept C2781406297 @default.
• W2973138923 hasConcept C50382708 @default.
• W2973138923 hasConcept C61367390 @default.
• W2973138923 hasConcept C71315377 @default.
• W2973138923 hasConcept C71924100 @default.
• W2973138923 hasConcept C72563966 @default.
• W2973138923 hasConceptScore W2973138923C121608353 @default.
• W2973138923 hasConceptScore W2973138923C126322002 @default.
• W2973138923 hasConceptScore W2973138923C126894567 @default.
• W2973138923 hasConceptScore W2973138923C143998085 @default.
• W2973138923 hasConceptScore W2973138923C2776551883 @default.
• W2973138923 hasConceptScore W2973138923C2776839432 @default.
• W2973138923 hasConceptScore W2973138923C2777899217 @default.
• W2973138923 hasConceptScore W2973138923C2777911890 @default.
• W2973138923 hasConceptScore W2973138923C2780192828 @default.
• W2973138923 hasConceptScore W2973138923C2781406297 @default.
• W2973138923 hasConceptScore W2973138923C50382708 @default.
• W2973138923 hasConceptScore W2973138923C61367390 @default.
• W2973138923 hasConceptScore W2973138923C71315377 @default.
• W2973138923 hasConceptScore W2973138923C71924100 @default.
• W2973138923 hasConceptScore W2973138923C72563966 @default.
• W2973138923 hasIssue "1" @default.
• W2973138923 hasLocation W29731389231 @default.
• W2973138923 hasOpenAccess W2973138923 @default.
• W2973138923 hasPrimaryLocation W29731389231 @default.
• W2973138923 hasRelatedWork W2169404610 @default.
• W2973138923 hasRelatedWork W2344231551 @default.
• W2973138923 hasRelatedWork W2435930479 @default.
• W2973138923 hasRelatedWork W2469134207 @default.
• W2973138923 hasRelatedWork W2770702948 @default.
• W2973138923 hasRelatedWork W2793295628 @default.
• W2973138923 hasRelatedWork W3030000199 @default.
• W2973138923 hasRelatedWork W4287355568 @default.
• W2973138923 hasRelatedWork W4310991221 @default.
• W2973138923 hasRelatedWork W4206870430 @default.
• W2973138923 hasVolume "105" @default.
• W2973138923 isParatext "false" @default.
• W2973138923 isRetracted "false" @default.
• W2973138923 magId "2973138923" @default.
• W2973138923 workType "article" @default.